OMDA Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: Q4 revenue reached $76 million, up 58% year-over-year; full-year revenue was $260 million, a 53% increase.

Members: Total members grew to 886,000, a 55% increase from 2024, with 55,000 net new additions in Q4.

Gross Profit: Q4 GAAP gross profit was $54 million (71% margin), while full-year gross profit was $171 million (66% margin).

Net Income: Achieved GAAP net income of $5 million in Q4, marking the first profitable quarter, with a full-year net loss of $13 million (improved from a $47 million loss in 2024).

Adjusted EBITDA: Q4 adjusted EBITDA was $8 million (11% margin); full-year adjusted EBITDA was $6 million (2% margin).

Cash Position: Ended the year with $222 million in cash, having generated positive operating cash flow.

2Strategic Updates and Business Highlights

Market Position: Established as a leader in GLP-1 companion care, with over 150,000 members utilizing GLP-1 programs.

AI Integration: Launched AI tools like OmadaSpark and Meal Map to enhance member engagement and support.

New Offerings: Introduced GLP-1 prescribing and GLP-1 Flex Care to broaden service offerings and enhance employer partnerships.

Multi-Condition Platform: Expanded into cholesterol management, complementing existing diabetes and hypertension programs, with significant growth in multi-condition adoption.

Enrollment Efficiency: Improved marketing effectiveness led to a 24% increase in enrollment rates year-over-year.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected revenue between $312 million and $322 million, reflecting 22% growth over 2025.

Adjusted EBITDA Guidance: Projected adjusted EBITDA between $7 million and $15 million, with potential upside from new product offerings not included in the initial guidance.

Growth Strategy: Focus on expanding covered lives, enhancing member engagement, and leveraging AI for operational efficiency.

4Bad News, Challenges, or Points of Concern

Market Risks: Concerns about potential impacts of decreasing GLP-1 drug prices on program demand; however, management believes lower prices could increase overall utilization.

Guidance Caution: The 2026 guidance is based on existing business metrics without significant improvements assumed, raising concerns about potential growth deceleration.

Seasonality Effects: Anticipated flat revenue in Q1 due to seasonal enrollment costs and the absence of the $2 million one-time revenue adjustment from Q4.

5Notable Q&A Insights

Enrollment Dynamics: Management emphasized that the guidance is conservative, relying on historical metrics without assuming improvements in conversion rates or engagement.

GLP-1 Flex Care Economics: This new offering is designed to provide structured support for employers not currently covering GLP-1s, potentially increasing revenue through enhanced service offerings.

AI Utilization: Management is optimistic about AI's role in enhancing operational efficiency and member engagement, viewing it as a competitive advantage rather than a disruption.

Multi-Condition Strategy: The company is witnessing strong growth in diabetes and hypertension programs, indicating a robust market for integrated care solutions beyond just GLP-1s. Overall, Omada Health demonstrated strong growth and strategic advancements in 2025, positioning itself well for continued expansion in 2026, despite facing market challenges and cautious guidance.